was approved in Europe in September as a subcutaneous injection offering a patient-friendly quarterly dosing schedule, as opposed to fortnightly and sometimes monthly dosing for Cimzia injections.

The US FDA has approved a label extension for UCB’s Cimzia (certolizumab pegol) for adults with moderate-to-severe plaque psoriasis, marking the company’s entry into immuno-dermatology ...

injection, 50 mg every month Certolizumab Cimzia® Human, pegylated monoclonal antibody sc. injection, 200–400 mg every 2–4 weeks OLT 3 (DE029) Healthy male and female subjects 120 25 mg/ml sc.